Clinical Trial Update: Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating NicVAX, a nicotine vaccine, for safety and effectiveness in nicotine-dependent individuals; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence
• Tobacco Use Disorder

Drugs mentioned

• NicVAX (nicotine vaccine)

Snippet

Sponsor: Nabi Biopharmaceuticals | Conditions: Smoking Cessation, Tobacco Use Cessation | Phase 2 | Status: COMPLETED